Mei Haruya’s Post

This weekend, a small piece of my work in the CHIVE and IMPACT programs, will be presented at the American Society of Hematology annual meeting in San Diego. This work provides a blueprint on delivering clinical trial access to underserved areas, while also providing contributions to Clonal Hematopoiesis (CH) research. We hope to expand this work to additional clinics, especially those in underserved areas. We also hope our research can contribute to the development of additional clinical trials for high-risk CH and to refining care protocols for CH. https://lnkd.in/eHTeUyyT

Haematology trial or hemato-oncology trial plans? Let's meet. PSI CRO AG is a leading CRO in blood disorders such as haemophilia and blood cancers such as leukemia, lymphoma and myeloma. Meet with my colleague Michael Sommer at #EHA2024 for a coffee and see how we can help you! European Hematology Association (EHA) #clinicaltrials #clinicaldevelopment #oncology #hematooncology #hemophilia #vonwillebranddisease #leukemia #lymphoma #myeloma #multiplemyeloma #kahlerdisease

The revolutionary breakthroughs that transform healthcare can seem like magic. But pioneering research is grounded in evidence, experimentation and endless evaluation. At Regeneron, we believe spellbinding science happens when curiosity drives innovation. Hear more from Lorah Perlee, VP, Hematology Global Program Head, on how we hope to reshape our understanding of what’s possible in hematology. #ASH2024 🧪✨🔬 https://bit.ly/3Bk7t8S

Outline your day at #ASH24 with Hematology Daily News by your side! Catch our first issue today ➙ https://lnkd.in/gCftGFmA

Attending ASH 2024, seeing first-hand the major scientific advances that are changing how multiple myeloma is treated and managed has been a truly inspiring experience. The progress we are witnessing is shifting the paradigm towards functional cure and the potential for a normal life expectancy.  The outlook for patients and the medical community is brighter than ever. However, with innovation comes new challenges, particularly in selecting the optimal approach. Transitioning from generalised treatments marked by cycles of remission and relapse, we are embracing personalised strategies across the care pathway. This means:  💡 Prioritising the best treatment first, where it can deliver the greatest impact on patient outcomes  💡 Enhancing, and prioritising patient experience by optimising regimens for improved tolerability, convenience and accessibility, looking not only at prolonging life but also providing a good quality of life  💡 Considering patient preferences and discussing treatment goals as part of shared decision-making  My colleague, Edmond K. Chan, captured what it was like to be at ASH hearing about these important updates. Take a look.   #ASH24 #InFrontOfCancer #mycompany 

I learned a lot at ASH 2024, deeply inspired by the clinicians and scientists who tirelessly advance science and bring new treatments to patients. Here are some key takeaways from the leading figures in hematology. #ASH #hematology

"Unlock the secrets of blood health with our Clinical Research Hematology Laboratory Course! Dive into the science of blood disorders, gain hands-on experience in advanced laboratory techniques, and learn from experts in the field. Join us on this journey to enhance patient outcomes through innovative hematological research!" 😊 🙂 🙂

To the pharma industry who ask for a guarantee of impact, or measure of impact of proper Patient Engagement: Let's turn it around... Show us that what you are doing works, that all your trials recruit well, and on time. Basically that your 80% failure rate is really great, and an acceptable by product in this industry... And that asking advocates for help to recruit to an impossible trial is also normal... Or ask them for extra QOL data which you 'forgot' to collect... Is this all really successful pharma business? Do some people really know what they are doing? Or is it time to listen for some real help? So no... I don't think we need to prove anything. There is enough proof that global methods don't work most of the time.

Register using the link below to join our webcast tonight at 9:00pm EST / 6:00pm PST to hear more about the progress shared today on DISC-0974 at #ASH24 and plans for next steps in development #Anemia in #Myelofibrosis. #DiscMedicine

Following the announcement of positive interim data from our Phase 2 trial of SNT-5505 in combination with ruxolitinib for treating myelofibrosis, CEO Gary Phillips speaks with JustStocks about the results presented this week at the 66th American Society of Hematology annual meeting. Watch here: https://lnkd.in/gDQC8Jir #Syntara #SNT5505 #Myelofibrosis #Biotech #ASX #ClinicalTrials #BreakthroughTherapy #SNT